Tofersen: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Tofersen. Educational only — not medical advice.

Labeled uses

QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies (14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Source: FDA labeling via NIH DailyMed (set 81356b45…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.